BioCentury
ARTICLE | Clinical News

Sustiva efavirenz regulatory update

April 13, 2015 7:00 AM UTC

EMA’s CHMP recommended approval of an expanded label for Merck’s Sustiva efavirenz to treat HIV-1 infection to include patients 3 months to 3 years old and weighing >=3.5 kg. The non-nucleoside revers...